The C10orf67 Knockout HeLa Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, targeting the C10orf67 gene. This gene-edited model enables loss-of-function studies of C10orf67, a predicted DNA-binding transcription factor. The polyclonal format provides a heterogeneous knockout pool generated by CRISPR/Cas9-mediated gene disruption, avoiding clonal artifacts and offering a genetically diverse population for robust functional analyses. This product is suitable for researchers investigating transcriptional regulation, cancer biology, and gene function, providing a versatile tool for dissecting the role of C10orf67 in cellular processes without relying on single-cell-derived clones.
HeLa cells are an immortalized epithelial cell line originally isolated from a cervical adenocarcinoma of a 31-year-old African American woman. Widely adopted in biomedical research, HeLa cells are well-characterized and amenable to genetic manipulation, making them an ideal host for CRISPR/Cas9 knockout studies. Their robust growth, stable karyotype, and extensive historical data enable reproducible experimental designs. As a carcinoma-derived line, HeLa cells retain dysregulated proliferation and survival pathways, providing a relevant context for examining the roles of transcription factors like C10orf67 in tumorigenesis. This host background facilitates investigations into the interplay between C10orf67 loss and cancer-associated phenotypes, particularly given the gene??s implication in prostate cancer susceptibility and other malignancies.
C10orf67 encodes a predicted DNA-binding transcription factor that is hypothesized to participate in RNA polymerase II-mediated transcription. Although its precise molecular interactions remain uncharacterized, it is proposed to function at DNA promoter regions, potentially cooperating with general transcription factors and RNA polymerase II to modulate target gene expression. The protein likely influences transcriptional programs controlling cell proliferation, a notion supported by its association with cancer susceptibility. Key representative pathway components include RNA polymerase II, general transcription factors, and DNA promoter elements, which collectively form the core transcriptional machinery. Disruption of C10orf67 in this polyclonal knockout population allows investigators to probe its role in transcriptional regulation and assess downstream effects on gene networks, despite the current lack of identified upstream regulators, downstream targets, or interacting partners.
In the context of HeLa cells, C10orf67 knockout offers a valuable model for exploring transcription factor function in a cancer-derived epithelial background. HeLa cells exhibit aberrant transcriptional landscapes driven by oncogenic alterations, and eliminating a putative regulator like C10orf67 may reveal its contribution to malignancy-associated gene expression patterns. Although C10orf67 has been genetically linked to prostate cancer susceptibility, functional studies in HeLa cells can elucidate conserved mechanisms of transcriptional control relevant to multiple cancer types. By examining phenotypic outcomes such as altered proliferation, apoptosis, or gene expression changes, researchers can infer the roles of C10orf67 in maintaining the transformed state. This model provides a platform to connect genetic ablation with cellular endpoints, filling critical knowledge gaps in C10orf67 biology.
This product supports a wide range of downstream applications, including gene function studies, transcriptional regulation analysis, and drug target validation. Researchers can employ RT-qPCR or RNA-seq to assess transcriptome-wide changes upon C10orf67 disruption, while ChIP-qPCR may be used to verify predicted DNA-binding activities. Functional assays such as cell proliferation, apoptosis, and western blotting for downstream effectors further characterize the knockout phenotype. Given the association with prostate cancer and other cancers, this model is particularly suited for mechanistic studies in tumor biology and for screening potential therapeutic compounds. For detailed technical specifications, protocols, and ordering information, please contact Ascent Research.
